Amal Therapeutics competitorsClear all
Amal Therapeutics's top competitors include Neovii, Eutilex and Foghorn Therapeutics.
 Amal Therapeutics Amal Therapeutics is a biotech company, which engages in the research and development of therapeutic vaccines in oncology. |  Neovii Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
|  Eutilex Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology. |  Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. | |
Founding Date | Founding Date N/A | Founding Date 2003 | Founding Date 2015 | Founding Date 2016 |
Type | Type Subsidiary | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations Genève, CH HQ | Locations Rapperswil-Jona, CH HQ Gräfelfing, DE Lexington, US | Locations KR HQ | Locations Cambridge, US HQ Cambridge, US |
Employees | Employees 225% increase | Employees 89 | Employees 108 | Employees 85 |
Alexa Website Rank | Alexa Website Rank 122274 | Alexa Website Rank N/A | Alexa Website Rank N/A | Alexa Website Rank 340238 |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ₩2b (FY, 2020) | Revenue (est.) $430k (FY, 2020) |
Net income | Net income N/A | Net income N/A | Net income (₩28.8b) (FY, 2020) | Net income ($68.8m) (FY, 2020) |
Funding | ||||
Total funding raised | Total funding raised $ 45.5m | Total funding raised N/A | Total funding raised $ 18.9m | Total funding raised $ 50m |
For sources of this data, please see the company profile
View company profiles
Neovii
HQ
Rapperswil-Jona, CH
Employees
89
Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
View companyEutilex
HQ
KR
Employees
108
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.
View companyFoghorn Therapeutics
HQ
Cambridge, US
Employees
85
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
View company